Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: docetaxel|DRUG: irinotecan hydrochloride
Sponsor: Alliance for Clinical Trials in Oncology
Collaborators: National Cancer Institute (NCI)